Wachowiak, R., H. Till, R. Metzger, U. Bierbach, T. Simon, B. Sattler, T. Aigner, O. Sabri, and R. Kluge, Residual lymph node metastasis in stage 4 neuroblastoma--advantage of radio-guided surgery? Pediatr Hematol Oncol, 2010. 27(6): p. 471-5.
Sudbrock, F., M. Schmidt, T. Simon, W. Eschner, F. Berthold, and H. Schicha, Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging, 2010. 37(7): p. 1279-90.
Simon, T., J. Kohlhase, C. Wilhelm, M. Kochanek, B. De Carolis, and F. Berthold, Multiple malignant diseases in a patient with Rothmund-Thomson syndrome with RECQL4 mutations: Case report and literature review. Am J Med Genet A, 2010. 152A(6): p. 1575-9.
Simon, T., M. Feldkotter, K. Buiting, M. Ortmann, H. Bolz, and F. Korber, Slow progression of a small Wilms' tumor. Klin Padiatr, 2010. 222(3): p. 190-1.
Simon, T., F. Berthold, A. Borkhardt, B. Kremens, B. De Carolis, and B. Hero, Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: Results of German trials. Pediatr Blood Cancer, 2010.
Shi, L., G. Campbell, W.D. Jones, F. Campagne, Z. Wen, S.J. Walker, Z. Su, T.M. Chu, F.M. Goodsaid, L. Pusztai, J.D. Shaughnessy, Jr., A. Oberthuer, R.S. Thomas, R.S. Paules, M. Fielden, B. Barlogie, W. Chen, P. Du, M. Fischer, C. Furlanello, B.D. Gallas, X. Ge, D.B. Megherbi, W.F. Symmans, M.D. Wang, J. Zhang, H. Bitter, B. Brors, P.R. Bushel, M. Bylesjo, M. Chen, J. Cheng, J. Chou, T.S. Davison, M. Delorenzi, Y. Deng, V. Devanarayan, D.J. Dix, J. Dopazo, K.C. Dorff, F. Elloumi, J. Fan, S. Fan, X. Fan, H. Fang, N. Gonzaludo, K.R. Hess, H. Hong, J. Huan, R.A. Irizarry, R. Judson, D. Juraeva, S. Lababidi, C.G. Lambert, L. Li, Y. Li, Z. Li, S.M. Lin, G. Liu, E.K. Lobenhofer, J. Luo, W. Luo, M.N. McCall, Y. Nikolsky, G.A. Pennello, R.G. Perkins, R. Philip, V. Popovici, N.D. Price, F. Qian, A. Scherer, T. Shi, W. Shi, J. Sung, D. Thierry-Mieg, J. Thierry-Mieg, V. Thodima, J. Trygg, L. Vishnuvajjala, S.J. Wang, J. Wu, Y. Wu, Q. Xie, W.A. Yousef, L. Zhang, X. Zhang, S. Zhong, Y. Zhou, S. Zhu, D. Arasappan, W. Bao, A.B. Lucas, F. Berthold, R.J. Brennan, A. Buness, J.G. Catalano, C. Chang, R. Chen, Y. Cheng, J. Cui, W. Czika, F. Demichelis, X. Deng, D. Dosymbekov, R. Eils, Y. Feng, J. Fostel, S. Fulmer-Smentek, J.C. Fuscoe, L. Gatto, W. Ge, D.R. Goldstein, L. Guo, D.N. Halbert, J. Han, S.C. Harris, C. Hatzis, D. Herman, J. Huang, R.V. Jensen, R. Jiang, C.D. Johnson, G. Jurman, Y. Kahlert, S.A. Khuder, M. Kohl, J. Li, M. Li, Q.Z. Li, S. Li, J. Liu, Y. Liu, Z. Liu, L. Meng, M. Madera, F. Martinez-Murillo, I. Medina, J. Meehan, K. Miclaus, R.A. Moffitt, D. Montaner, P. Mukherjee, G.J. Mulligan, P. Neville, T. Nikolskaya, B. Ning, G.P. Page, J. Parker, R.M. Parry, X. Peng, R.L. Peterson, J.H. Phan, B. Quanz, Y. Ren, S. Riccadonna, A.H. Roter, F.W. Samuelson, M.M. Schumacher, J.D. Shambaugh, Q. Shi, R. Shippy, S. Si, A. Smalter, C. Sotiriou, M. Soukup, F. Staedtler, G. Steiner, T.H. Stokes, Q. Sun, P.Y. Tan, R. Tang, Z. Tezak, B. Thorn, M. Tsyganova, Y. Turpaz, S.C. Vega, R. Visintainer, J. von Frese, C. Wang, E. Wang, J. Wang, W. Wang, F. Westermann, J.C. Willey, M. Woods, S. Wu, N. Xiao, J. Xu, L. Xu, L. Yang, X. Zeng, M. Zhang, C. Zhao, R.K. Puri, U. Scherf, W. Tong and R.D. Wolfinger, The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol, 2010. 28(8): p. 827-38.
Schmidt, M., R.P. Baum, T. Simon, and R. Howman-Giles, Therapeutic nuclear medicine in pediatric malignancy. Q J Nucl Med Mol Imaging, 2010. 54(4): p. 411-28.
Paulides, M., W. Stohr, H.J. Laws, N. Graf, M. Lakomek, F. Berthold, K. Schmitt, F. Niggli, H. Jurgens, S. Bielack, E. Koscielniak, T. Klingebiel, and T. Langer, Immunity against tetanus and diphtheria after childhood sarcoma treatment. Klin Padiatr, 2010. 222(3): p. 196.
Parry, R.M., W. Jones, T.H. Stokes, J.H. Phan, R.A. Moffitt, H. Fang, L. Shi, A. Oberthuer, M. Fischer, W. Tong, and M.D. Wang, k-Nearest neighbor models for microarray gene expression analysis and clinical outcome prediction. Pharmacogenomics J, 2010. 10(4): p. 292-309.
Oberthuer, A., D. Juraeva, L. Li, Y. Kahlert, F. Westermann, R. Eils, F. Berthold, L. Shi, R.D. Wolfinger, M. Fischer, and B. Brors, Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients. Pharmacogenomics J, 2010. 10(4): p. 258-66.
Oberthuer, A., B. Hero, F. Berthold, D. Juraeva, A. Faldum, Y. Kahlert, S. Asgharzadeh, R. Seeger, P. Scaruffi, G.P. Tonini, I. Janoueix-Lerosey, O. Delattre, G. Schleiermacher, J. Vandesompele, J. Vermeulen, F. Speleman, R. Noguera, M. Piqueras, J. Benard, A. Valent, S. Avigad, I. Yaniv, A. Weber, H. Christiansen, R.G. Grundy, K. Schardt, M. Schwab, R. Eils, P. Warnat, L. Kaderali, T. Simon, B. Decarolis, J. Theissen, F. Westermann, B. Brors, and M. Fischer, Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol, 2010. 28(21): p. 3506-15.
Muth, D., S. Ghazaryan, I. Eckerle, E. Beckett, C. Pohler, J. Batzler, C. Beisel, S. Gogolin, M. Fischer, K.O. Henrich, V. Ehemann, P. Gillespie, M. Schwab, and F. Westermann, Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma. Cancer Res, 2010. 70(9): p. 3791-802.
Meinhardt, A., B. Burkhardt, M. Zimmermann, A. Borkhardt, U. Kontny, T. Klingebiel, F. Berthold, G. Janka-Schaub, C. Klein, E. Kabickova, W. Klapper, A. Attarbaschi, M. Schrappe, and A. Reiter, Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol, 2010. 28(19): p. 3115-21.
Fischer, M., Berthold, F., The role of complex genomic alterations in neuroblastoma risk estimation. Genome Medicine, 2010. 2: p. 31.
De Preter, K., J. Vermeulen, B. Brors, O. Delattre, A. Eggert, M. Fischer, I. Janoueix-Lerosey, C. Lavarino, J.M. Maris, J. Mora, A. Nakagawara, A. Oberthuer, M. Ohira, G. Schleiermacher, A. Schramm, J.H. Schulte, Q. Wang, F. Westermann, F. Speleman, and J. Vandesompele, Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res, 2010. 16(5): p. 1532-41.
Boztug, K., X.Q. Ding, H. Hartmann, L. Ziesenitz, A.A. Schaffer, J. Diestelhorst, D. Pfeifer, G. Appaswamy, S. Kehbel, T. Simon, A. Al Jefri, H. Lanfermann, and C. Klein, HAX1 mutations causing severe congenital neuropenia and neurological disease lead to cerebral microstructural abnormalities documented by quantitative MRI. Am J Med Genet A, 2010. 152A(12): p. 3157-63.
Ackermann, S., F. Goeser, J.H. Schulte, A. Schramm, V. Ehemann, B. Hero, A. Eggert, F. Berthold, and M. Fischer, Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma. Clin Cancer Res, 2010.
Voth, H., A. Oberthuer, T. Simon, Y. Kahlert, F. Berthold, and M. Fischer, Co-regulated expression of HAND2 and DEIN by a bidirectional promoter with asymmetrical activity in neuroblastoma. BMC Mol Biol, 2009. 10: p. 28.
Vermeulen, J., K. De Preter, A. Naranjo, L. Vercruysse, N. Van Roy, J. Hellemans, K. Swerts, S. Bravo, P. Scaruffi, G.P. Tonini, B. De Bernardi, R. Noguera, M. Piqueras, A. Canete, V. Castel, I. Janoueix-Lerosey, O. Delattre, G. Schleiermacher, J. Michon, V. Combaret, M. Fischer, A. Oberthuer, P.F. Ambros, K. Beiske, J. Benard, B. Marques, H. Rubie, J. Kohler, U. Potschger, R. Ladenstein, M.D. Hogarty, P. McGrady, W.B. London, G. Laureys, F. Speleman, and J. Vandesompele, Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol, 2009. 10(7): p. 663-71.
Theissen, J., M. Boensch, R. Spitz, D. Betts, S. Stegmaier, H. Christiansen, F. Niggli, F. Schilling, M. Schwab, T. Simon, F. Westermann, F. Berthold, and B. Hero, Heterogeneity of the MYCN oncogene in neuroblastoma. Clin Cancer Res, 2009. 15(6): p. 2085-90.
Stutterheim, J., A. Gerritsen, L. Zappeij-Kannegieter, B. Yalcin, R. Dee, M.M. van Noesel, F. Berthold, R. Versteeg, H.N. Caron, C.E. van der Schoot, and G.A. Tytgat, Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clin Chem, 2009. 55(7): p. 1316-26.
Rutkowski, S., N.U. Gerber, K. von Hoff, A. Gnekow, U. Bode, N. Graf, F. Berthold, G. Henze, J.E. Wolff, M. Warmuth-Metz, N. Soerensen, A. Emser, H. Ottensmeier, F. Deinlein, P.G. Schlegel, R.D. Kortmann, T. Pietsch, and J. Kuehl, Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. Neuro Oncol, 2009. 11(2): p. 201-10.
Oehme, I., H.E. Deubzer, D. Wegener, D. Pickert, J.P. Linke, B. Hero, A. Kopp-Schneider, F. Westermann, S.M. Ulrich, A. von Deimling, M. Fischer, and O. Witt, Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res, 2009. 15(1): p. 91-9.
Oberthuer, A., J. Theissen, F. Westermann, B. Hero, and M. Fischer, Molecular characterization and classification of neuroblastoma. Future Oncol, 2009. 5(5): p. 625-39.
Nevo, I., A. Oberthuer, E. Botzer, O. Sagi-Assif, S. Maman, M. Pasmanik-Chor, N. Kariv, M. Fischer, I. Yron, and I.P. Witz, Gene-expression-based analysis of local and metastatic neuroblastoma variants reveals a set of genes associated with tumor progression in neuroblastoma patients. Int J Cancer, 2009. 126(7): p. 1570-81.
Monclair, T., G.M. Brodeur, P.F. Ambros, H.J. Brisse, G. Cecchetto, K. Holmes, M. Kaneko, W.B. London, K.K. Matthay, J.G. Nuchtern, D. von Schweinitz, T. Simon, S.L. Cohn, and A.D. Pearson, The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol, 2009. 27(2): p. 298-303.
Lange, L., T. Simon, B. Ibach, and E. Rietschel, [Shwachman-diamond syndrome as cause of infantile eczema associated with failure to thrive]. Klin Padiatr, 2009. 221(2): p. 89-92.
Kaatsch, P., I. Reinisch, C. Spix, F. Berthold, G. Janka-Schaub, A. Mergenthaler, . Michaelis, and M. Blettner, Case-control study on the therapy of childhood cancer and the occurrence of second malignant neoplasms in Germany. Cancer Causes Control, 2009. 20(6): p. 965-80.
Hoene, V., M. Fischer, A. Ivanova, T. Wallach, F. Berthold, and C. Dame, GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes. Br J Cancer, 2009. 101(8): p. 1481-9.
Harel, L., B. Costa, M. Tcherpakov, M. Zapatka, A. Oberthuer, L.M. Hansford, M. Vojvodic, Z. Levy, Z.Y. Chen, F.S. Lee, S. Avigad, I. Yaniv, L. Shi, R. Eils, M. Fischer, B. Brors, D.R. Kaplan, and M. Fainzilber, CCM2 mediates death signaling by the TrkA receptor tyrosine kinase. Neuron, 2009. 63(5): p. 585-91.
Galldiks, N., L.W. Kracht, F. Berthold, H. Miletic, J.C. Klein, K. Herholz, A.H. Jacobs, and W.D. Heiss, [(11)C]-L: -Methionine positron emission tomography in the management of children and young adults with brain tumors. J Neurooncol, 2009.
Fischer, M., T. Bauer, A. Oberthur, B. Hero, J. Theissen, M. Ehrich, R. Spitz, R. Eils, F. Westermann, B. Brors, R. Konig, and F. Berthold, Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. Oncogene, 2009. 29(6): p. 865-75.
Eckerle, I., D. Muth, J. Batzler, K.O. Henrich, W. Lutz, M. Fischer, O. Witt, M. Schwab, and F. Westermann, Regulation of BIRC5 and its isoform BIRC5-2B in neuroblastoma. Cancer Lett, 2009. 285(1): p. 99-107.
Cohn, S.L., A.D. Pearson, W.B. London, T. Monclair, P.F. Ambros, G.M. Brodeur, A. Faldum, B. Hero, T. Iehara, D. Machin, V. Mosseri, T. Simon, A. Garaventa, V. Castel, and K.K. Matthay, The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol, 2009. 27(2): p. 289-97.
Benz-Bohm, G., B. Hero, A. Gossmann, T. Simon, F. Korber, and F. Berthold, Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma: how much diagnostic imaging is necessary? Eur J Radiol, 2009. 74(3): p. e1-5.
Wilken, B., M. Baumann, C.G. Bien, B. Hero, K. Rostasy, and F. Hanefeld, Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses. Eur J Paediatr Neurol, 2008. 12(1): p. 51-5.
Westermann, F., D. Muth, A. Benner, T. Bauer, K.O. Henrich, A. Oberthuer, B. Brors, T. Beissbarth, J. Vandesompele, F. Pattyn, B. Hero, R. Konig, M. Fischer, and M. Schwab, Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol, 2008. 9(10): p. R150.
Stutterheim, J., A. Gerritsen, L. Zappeij-Kannegieter, I. Kleijn, R. Dee, L. Hooft, M.M. van Noesel, M. Bierings, F. Berthold, R. Versteeg, H.N. Caron, C.E. van der Schoot, and G.A. Tytgat, PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol, 2008. 26(33): p. 5443-9.
Simon, T., B. Hero, G. Benz-Bohm, D. von Schweinitz, and F. Berthold, Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial. Pediatr Blood Cancer, 2008. 50(5): p. 965-9.
Schmidt, M., T. Simon, B. Hero, H. Schicha, and F. Berthold, The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer, 2008. 44(11): p. 1552-8.
Pawlowski, M., A. Kouklinos, G. Jopp-Petzina, P. Herkenrath, M. Fischer, A. Kribs, B. Roth, J. Roth, and K. Tenbrock, G/A polymorphism at -258 of the hepatic glucokinase promoter is not associated with decreased birth weight in preterm neonates. Neonatology, 2008. 94(2): p. 71-4.
Oberthuer, A., L. Kaderali, Y. Kahlert, B. Hero, F. Westermann, F. Berthold, B. Brors, R. Eils, and M. Fischer, Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR. Clin Cancer Res, 2008. 14(20): p. 6590-601.
Nowacki, S., M. Skowron, A. Oberthuer, A. Fagin, H. Voth, B. Brors, F. Westermann, A. Eggert, B. Hero, F. Berthold, and M. Fischer, Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma. Oncogene, 2008. 27(23): p. 3329-38.
Miletic, H., R. Rohling, W. Stenzel, M. Deckert, G. Benz-Bohm, F. Berthold, and J. Voges, 8-year-old child with a lesion in the left nucleus lentiformis. Brain Pathol, 2008. 18(4): p. 598-601.
Hero, B., Berthold, F., Neuroblastoma. Leitlinien Kinderheilkunde und Jugendmedizin, ed. D. Reinhardt. 2008: Urban & Fischer. L5 1-5.
Hero, B., Simon, T., Spitz, R., Ernestus, K., Gnekow, A., Scheel-Walter, HG., Schwabe, D., Schilling, FH., Benz-Bohm, G., Berthold, F., Localized infant neuroblastomas often show spontaneous regression: Results of the prospective trials NB95-S and NB97. J Clin Oncol, 2008. 26(9): p. 1504-1509.
Funk, M.B., B. Buchholz, G. Notheis, J. Neubert, C. Feiterna-Sperling, R. Ganschow, T. Simon, F. Hornemann, A.M. Peters, H. Rutschle, G. Horneff, E. Lechner, K.M. Hanschmann, and U. Wintergerst, Disease progression in HIV-1 infected children and adolescents--results of a German-Austrian cohort study. Eur J Med Res, 2008. 13(8): p. 371-8.
Franzius, C., M. Schmidt, B. Hero, T. Pfluger, and K. Hahn, [Procedure guidelines for MIBG-scintigraphy in children]. Nuklearmedizin, 2008. 47(3): p. 132-8.
Fischer, M., R. Spitz, A. Oberthur, F. Westermann, and F. Berthold, Risk estimation of neuroblastoma patients using molecular markers. Klin Padiatr, 2008. 220(3): p. 137-46.
Ertle, F., W. Behnisch, N.A. Al Mulla, M. Bessisso, D. Rating, G. Mechtersheimer, B. Hero, and A.E. Kulozik, Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses. Pediatr Blood Cancer, 2008. 50(3): p. 683-7.
Benard, J., G. Raguenez, A. Kauffmann, A. Valent, H. Ripoche, V. Joulin, B. Job, G. Danglot, S. Cantais, T. Robert, M.J. Terrier-Lacombe, A. Chassevent, S. Koscielny, M. Fischer, F. Berthold, M. Lipinski, T. Tursz, P. Dessen, V. Lazar, and D. Valteau-Couanet, MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Mol Oncol, 2008. 2(3): p. 261-71.
Westermann, F., K.O. Henrich, J.S. Wei, W. Lutz, M. Fischer, R. Konig, R. Wiedemeyer, V. Ehemann, B. Brors, K. Ernestus, I. Leuschner, A. Benner, J. Khan, and M. Schwab, High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status. Clin Cancer Res, 2007. 13(16): p. 4695-703.
Warnat, P., A. Oberthuer, M. Fischer, F. Westermann, R. Eils, and B. Brors, Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes. BMC Cancer, 2007. 7: p. 89.
Voth, H., A. Oberthuer, T. Simon, Y. Kahlert, F. Berthold, and M. Fischer, Identification of DEIN, a novel gene with high expression levels in stage IVS neuroblastoma. Mol Cancer Res, 2007. 5(12): p. 1276-84.
Simon, T., A. Langler, U. Harnischmacher, M.C. Fruhwald, N. Jorch, A. Claviez, F. Berthold, and B. Hero, Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. J Cancer Res Clin Oncol, 2007.
Simon, T., A. Langler, F. Berthold, T. Klingebiel, and B. Hero, Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial. J Pediatr Hematol Oncol, 2007. 29(2): p. 101-6.
Opel, D., C. Poremba, T. Simon, K.M. Debatin, and S. Fulda, Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res, 2007. 67(2): p. 735-45.
Oberthuer, A., P. Warnat, Y. Kahlert, F. Westermann, R. Spitz, B. Brors, B. Hero, R. Eils, M. Schwab, F. Berthold, and M. Fischer, Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. Cancer Lett, 2007. 250(2): p. 250-267.
Koch, A., A. Hrychyk, W. Hartmann, A. Waha, T. Mikeska, U. Schuller, N. Sorensen, F. Berthold, C.G. Goodyer, O.D. Wiestler, W. Birchmeier, J. Behrens, and T. Pietsch, Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF-dependent transcription in medulloblastomas. Int J Cancer, 2007. 121(2): p. 284-91.
Jensen, M. and F. Berthold, Targeting the neural cell adhesion molecule in cancer. Cancer Lett, 2007. 258(1): p. 9-21.
Jensen, M., Klehr, M., Vogel, A., Schmitz, S., Tawadros, S., Mühlenhoff, M., Plück, A., Fischer, T., Schomäcker, K., Schultze, JL., Berthold, F., One step generation of fully chimeric antibodies using Cy1-and Ck mutant mice. J Immunother, 2007. 30: p. 338-349.
Gobel, U., H. Jurgens, A. Christaras, F. Berthold, and T. Klingebiel, Erfahrungen mit dem G-DRG-System funf Jahre nach seiner Einfuhrung aus Sicht der Gesellschaft fur Padiatrische Onkologie und Hamatologie (GPOH). Klin Padiatr, 2007. 219(6): p. 303-5.
Berthold, F., Neuroblastoma, in Therapiekonzepte Onkologie, S. Seeber, Schütte, J., Editor. 2007, Springer: Heidelberg. p. 1023-1030.
Wagner, S., M. Warmuth-Metz, A. Emser, A.K. Gnekow, R. Strater, S. Rutkowski, N. Jorch, H.J. Schmid, F. Berthold, N. Graf, R.D. Kortmann, T. Pietsch, N. Sorensen, O. Peters, and J.E. Wolff, Treatment options in childhood pontine gliomas. J Neurooncol, 2006. 79(3): p. 281-7.
Wagner, S., M. Benesch, F. Berthold, A.K. Gnekow, S. Rutkowski, R. Strater, M. Warmuth-Metz, R.D. Kortmann, T. Pietsch, and J.E. Wolff, Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas. Br J Cancer, 2006. 95(8): p. 991-7.
Sudbrock, F., W. Eschner, M. Schmidt, T. Simon, B. Hero, and H. Schicha, [Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG]. Nuklearmedizin, 2006. 45(6): p. 254-61.
Spitz, R., A. Oberthuer, M. Zapatka, B. Brors, B. Hero, K. Ernestus, J. Oestreich, M. Fischer, T. Simon, and F. Berthold, Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer, 2006. 45(12): p. 1130-42.
Spitz, R., B. Hero, T. Simon, and F. Berthold, Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res, 2006. 12(11 Pt 1): p. 3368-73.
Spitz, R., D.R. Betts, T. Simon, M. Boensch, J. Oestreich, F.K. Niggli, K. Ernestus, F. Berthold, and B. Hero, Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma. Cancer Genet Cytogenet, 2006. 167(1): p. 51-6.
Simon, T., R. Spitz, B. Hero, F. Berthold, and A. Faldum, Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q. Cancer Lett, 2006. 237(2): p. 215-22.
Simon, T., B. Hero, R. Bongartz, M. Schmidt, R.P. Muller, and F. Berthold, Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease. Strahlenther Onkol, 2006. 182(7): p. 389-94.
Schmidt, M., T. Simon, B. Hero, W. Eschner, M. Dietlein, F. Sudbrock, R. Bongartz, F. Berthold, and H. Schicha, Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin, 2006. 45(4): p. 145-51; quiz N39-40.
Rostasy, K., B. Wilken, M. Baumann, K. Muller-Deile, I. Bieber, J. Gartner, P. Moller, P. Angelini, and B. Hero, High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome. Neuropediatrics, 2006. 37(5): p. 291-5.
Otto, C., M. Jensen, M. Dietlein, T. Fischer, M. Schmidt, S. Tawadros, S.M. Borner, S.A. Weber, R. Spitz, W. Bloch, F. Berthold, H. Schicha, and K. Schomacker, Localization of 131I-labelled monoclonal antibody ERIC1 in a subcutaneous xenograft model of neuroblastoma in SCID mice. Nucl Med Commun, 2006. 27(2): p. 171-8.
Oberthuer, A., F. Berthold, P. Warnat, B. Hero, Y. Kahlert, R. Spitz, K. Ernestus, R. Konig, S. Haas, R. Eils, M. Schwab, B. Brors, F. Westermann, and M. Fischer, Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol, 2006. 24(31): p. 5070-8.
Hufnagel, M., A. Claviez, N. Czech, M. Schmidt, and B. Hero, Neuroblastoma stage 4S with 123I-MIBG-positive bone marrow involvement. Pediatr Blood Cancer, 2006. 46(2): p. 264-5.
Hero, B., Berthold, F., Neuroblastom, in Kurzgefasste interdisziplinäre Leitlinien 2006, A. Garbe, Beckmann, Editor. 2006, Zuckschwerdt Verlag. p. 508-511.
Henrich, K.O., M. Fischer, D. Mertens, A. Benner, R. Wiedemeyer, B. Brors, A. Oberthuer, F. Berthold, J.S. Wei, J. Khan, M. Schwab, and F. Westermann, Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients. Clin Cancer Res, 2006. 12(1): p. 131-8.
Fulda, S., C. Poremba, B. Berwanger, S. Hacker, M. Eilers, H. Christiansen, B. Hero, and K.M. Debatin, Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma. Cancer Res, 2006. 66(20): p. 10016-23.
Fischer, M., A. Oberthuer, B. Brors, Y. Kahlert, M. Skowron, H. Voth, P. Warnat, K. Ernestus, B. Hero, and F. Berthold, Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clin Cancer Res, 2006. 12(17): p. 5118-28.
Ernestus, K., T. Pietsch, M. Gessler, T. Simon, B. Hero, and F. Berthold, [Structure, use, and risks of biomaterial repositories of embryonal tumors]. Klin Padiatr, 2006. 218(3): p. 132-8.
Berthold, F., G. Bode, A. Bocker, A. Christaras, U. Creutzig, G. Henze, R. Herold, A. Heyll, J. Malzahn, T. Rath, and H. Jurgens, [Measures of quality assurance for in-patient pediatric oncology units]. Klin Padiatr, 2006. 218(6): p. 293-5.
Wolfl, M., A.A. Jungbluth, F. Garrido, T. Cabrera, S. Meyen-Southard, R. Spitz, K. Ernestus, and F. Berthold, Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother, 2005. 54(4): p. 400-6.
Simon, T., B. Hero, A. Faldum, R. Handgretinger, M. Schrappe, D. Niethammer, and F. Berthold, Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy. Klin Padiatr, 2005. 217(3): p. 147-52.
Simon, T., [Neuroblastoma]. Urologe A, 2005. 44(5): p. 543-54; 555.
Schumacher-Kuckelkorn, R., B. Hero, K. Ernestus, and F. Berthold, Lacking immunocytological GD2 expression in neuroblastoma: report of 3 cases. Pediatr Blood Cancer, 2005. 45(2): p. 195-201.
Oberthuer, A., M. Skowron, R. Spitz, Y. Kahlert, F. Westermann, K. Mehler, F. Berthold, and M. Fischer, Characterization of a complex genomic alteration on chromosome 2p that leads to four alternatively spliced fusion transcripts in the neuroblastoma cell lines IMR-5, IMR-5/75 and IMR-32. Gene, 2005. 363: p. 41-50.
Matthay, K.K., F. Blaes, B. Hero, D. Plantaz, P. De Alarcon, W.G. Mitchell, M. Pike, and V. Pistoia, Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett, 2005. 228(1-2): p. 275-82.
London, W.B., L. Boni, T. Simon, F. Berthold, C. Twist, M.L. Schmidt, R.P. Castleberry, K.K. Matthay, S.L. Cohn, and B. De Bernardi, The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives. Cancer Lett, 2005. 228(1-2): p. 257-66.
Ladenstein, R., Berthold, F., Ambros, I., Ambros, P., Neuroblastome, in Pädiatrische Hämatologie und Onkologie, H. Gadner, Gaedicke, G., Niemeyer, R., Ritter, J., Editor. 2005, Springer Verlag. p. 829-846.
Hess, J.R., L.R. Kagen, P.F. van der Meer, T. Simon, R. Cardigan, T.J. Greenwalt, J.P. AuBuchon, A. Brand, W. Lockwood, A. Zanella, J. Adamson, E. Snyder, H.L. Taylor, G. Moroff, and C. Hogman, Interlaboratory comparison of red-cell ATP, 2,3-diphosphoglycerate and haemolysis measurements. Vox Sang, 2005. 89(1): p. 44-8.
Hero, B., Berthold, F., Neuroblastoma, in Leitlinien Kinderheilkunde und Jugendmedizin, D. Reinhardt, Editor. 2005, Urban & Fischer. p. L5 1-5.
Fischer, M., M. Skowron, and F. Berthold, Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA. J Mol Diagn, 2005. 7(1): p. 89-96.
Fischer, M., Oberthuer, A., von Schweinitz, D., Simon, T., Das Neuroblastom. Der Onkologe, 2005. 11: p. 1054-1064.
Feldman, A.L., F. Berthold, R.J. Arceci, C. Abramowsky, B.M. Shehata, K.P. Mann, S.J. Lauer, J. Pritchard, M. Raffeld, and E.S. Jaffe, Clonal relationship between precursor T-lymphoblastic leukaemia/lymphoma and Langerhans-cell histiocytosis. Lancet Oncol, 2005. 6(6): p. 435-7.
Eich, H.T., R.P. Muller, O. Micke, M. Kocher, F. Berthold, and B. Hero, Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment? Strahlenther Onkol, 2005. 181(6): p. 378-84.
De Bernardi, B., W. Balwierz, J. Bejent, S.L. Cohn, M.L. Garre, T. Iehara, D. Plantaz, T. Simon, P. Angelini, A. Cama, W.B. London, K. Kramer, H.M. Katzenstein, P. Tortori-Donati, A. Rossi, G.J. D'Angio, and A.E. Evans, Epidural compression in neuroblastoma: Diagnostic and therapeutic aspects. Cancer Lett, 2005. 228(1-2): p. 283-99.
Boensch, M., A. Oberthuer, M. Fischer, M. Skowron, J. Oestreich, F. Berthold, and R. Spitz, Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q. Diagn Mol Pathol, 2005. 14(3): p. 177-82.
Blaes, F., V. Fuhlhuber, M. Korfei, M. Tschernatsch, W. Behnisch, K. Rostasy, B. Hero, M. Kaps, and K.T. Preissner, Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol, 2005. 58(2): p. 313-7.
Berthold, F., J. Boos, S. Burdach, R. Erttmann, G. Henze, J. Hermann, T. Klingebiel, B. Kremens, F.H. Schilling, M. Schrappe, T. Simon, and B. Hero, Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol, 2005. 6(9): p. 649-58.
Berthold, F., Neuroblastom, in Kompendium Internistische Onkologie, H. Schmoll, Possinger, Editor. 2005, Springer Verlag. p. 843-846.
Berthold, F., Simon, T., Clinical Presentation, in Neuroblastoma, N.K. Cheung, Cohn, S.L., Editor. 2005, Springer Verlag. p. 63-85.
Benesch, M., S. Wagner, F. Berthold, and J.E. Wolff, Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH). J Neurooncol, 2005. 72(2): p. 179-83
